Study Comparing XL092 and Atezolizumab with Regorafenib for Metastatic Colorectal Cancer

Inclusion Criteria

• Have a confirmed diagnosis of colon or rectal cancer.
• Have documented RAS gene status (either mutated or normal).
• Do not have high microsatellite instability or mismatch repair deficiency in the cancer.
• Have received standard cancer treatments for metastatic colorectal cancer but the cancer has progressed or the patient cannot tolerate these treatments.
• Have measurable cancer according to specific medical criteria.
• Can provide a previous or new tumor sample for analysis.
• Have recovered from any side effects of previous treatments to a mild level or better.
• Have a performance status score of 0 or 1, indicating full activity or some restriction in strenuous activities.
• Have adequate organ and bone marrow function.
• Agree to use effective contraception during and after the study if fertile.
• Women must not be pregnant at the start of the study.

Exclusion Criteria

• Have previously been treated with XL092, regorafenib, or certain other cancer drugs.
• Have taken a small molecule kinase inhibitor within 2 weeks before starting the study.
• Have received any type of cancer antibody therapy, chemotherapy, or hormonal therapy within 3 weeks (or bevacizumab within 4 weeks) before starting the study.
• Have had radiation therapy for bone metastasis within 2 weeks, or any other radiation therapy within 4 weeks before starting the study.
• Have untreated or unstable brain metastases.
• Have uncontrolled or significant recent illness.
• Have had major surgery within 4 weeks before starting the study.
• Are taking corticosteroids or other immunosuppressive medications within 14 days before starting the study.
• Have a heart condition affecting the QT interval on an ECG.
• Have a psychiatric illness that may interfere with the study.
• Are pregnant or breastfeeding.
• Cannot swallow pills or have a condition affecting drug absorption.
• Have allergies to the study drugs.
• Have another active cancer or had another cancer diagnosis within 2 years before starting the study.
• Have received a live vaccine within 30 days before starting the study.